To boast for getting listed on market,International Trademarks Agent Traders(Abbreviated as ITAT) has spent large amount of expenses to hold royal entertainment parties in Hong Kong,XiAn,ShenZhen and BeiJing. In ShenZ...To boast for getting listed on market,International Trademarks Agent Traders(Abbreviated as ITAT) has spent large amount of expenses to hold royal entertainment parties in Hong Kong,XiAn,ShenZhen and BeiJing. In ShenZhen,where the headquarters of this company is located,you could see their TV advertisement,print advertisement and outdoor bus advertisement around everywhere.展开更多
The crystal structure evolution of the Cu-rich nano precipitates from bcc to 9R during thermal aging was studied in nuclear reactor pressure vessel （RPV） model steels. The specimens, contained higher copper and nick...The crystal structure evolution of the Cu-rich nano precipitates from bcc to 9R during thermal aging was studied in nuclear reactor pressure vessel （RPV） model steels. The specimens, contained higher copper and nickel contents than commercially available one, were heated at 890 ~C for 0.5 h and then water quenched followed by tempering at 0（50 ~C for I0 h and aging at 400 ~C for 1000 h. It was observed that bcc and 9R orthogonal structure, as well as 9R orthogonal and 9R monoclinic structure, coexist in a single Cu-rich nano precipitate. Further analyses pointed out that Cu-rich nano precipitates of bcc structure were not stable, it may preferentially transform to 9R orthogonal structure and then to 9R monoclinic structure. This results showed that the crystal structure evolution of the Cu-rich nano precipitates was complex.展开更多
Background and Objective. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through the addition of peptides, such as sinapultide, that mimic the action of human surfactan...Background and Objective. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through the addition of peptides, such as sinapultide, that mimic the action of human surfactant protein-B (SP-B). A synthetic surfactant containing a mimic of SP-B may also reduce the potential risks associated with the use of animal-derived products. Our objective was to compare the efficacy and safety of a novel synthetic surfactant containing a functional SP-B mimic (lucinactant; Discovery Laboratories, Doylestown, PA) with those of a non-protein-containing synthetic surfactant (colfosceril palmitate; Glaxo Smith Kline, Brentford, United Kingdom) and a bovine-derived surfactant (beractant; Abbott Laboratories, Abbott Park, IL) in the prevention of neonatal respiratory distress syndrome (RDS) and RDS-related death. Methods. We assigned randomly (double-masked) 1294 very preterm infants, weighing 600 to 1250 g and of ≤32 weeks gestational age, to receive colfosceril palmitate (n=509), lucinactant (n=527), or beractant (n=258) within 20 to 30 minutes after birth. Primary outcome measures were the rates of RDS at 24 hours and the rates of death related to RDS during the first 14 days after birth. All-cause mortality rates, bronchopulmonary dysplasia (BPD) rates, and rates of other complications of prematurity were prespecified secondary outcomes. Primary outcomes, air leaks, and causes of death were assigned by an independent, masked, adjudication committee with prespecified definitions. The study was monitored by an independent data safety monitoring board. Results. Lucinactant reduced significantly the incidence of RDS at 24 hours,compared with colfosceril (39.1%vs 47.2%; odds ratio [OR]: 0.68; 95%confidence interval [CI]: 0.52-0.89). There was no significant difference in comparison with beractant (33.3%). However, lucinactant reduced significantly RDS-related mortality rates by 14 days of life, compared with both colfosceril (4.7%vs 9.4%; OR: 0.43; 95%CI: 0.25-0.73) and beractant (10.5%; OR: 0.35; 95%CI: 0.18-0.66). In addition, BPD at 36 weeks postmenstrual age was significantly less common with lucinactant than with colfosceril (40.2%vs 45.0%; OR: 0.75; 95%CI: 0.56-0.99), and the all-cause mortality rate at 36 weeks postmenstrual age was lower with lucinactant than with beractant (21%vs 26%; OR: 0.67; 95%CI: 0.45-1.00). Conclusions. Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS. In addition, lucinactant reduces the incidence of BPD, compared with colfosceril palmitate, and decreases RDS-related mortality rates, compared with beractant. Therefore, we conclude that lucinactant, the first of a new class of surfactants containing a functional protein analog of SP-B, is an effective therapeutic option for preterm infants at risk for RDS.展开更多
文摘To boast for getting listed on market,International Trademarks Agent Traders(Abbreviated as ITAT) has spent large amount of expenses to hold royal entertainment parties in Hong Kong,XiAn,ShenZhen and BeiJing. In ShenZhen,where the headquarters of this company is located,you could see their TV advertisement,print advertisement and outdoor bus advertisement around everywhere.
基金financially supported by the National Basic Research Program of China(No.2011CB610503)National Natural Science Foundation of China(No.50931003)Ministry of Major Subject of Shanghai(No.S30107)
文摘The crystal structure evolution of the Cu-rich nano precipitates from bcc to 9R during thermal aging was studied in nuclear reactor pressure vessel （RPV） model steels. The specimens, contained higher copper and nickel contents than commercially available one, were heated at 890 ~C for 0.5 h and then water quenched followed by tempering at 0（50 ~C for I0 h and aging at 400 ~C for 1000 h. It was observed that bcc and 9R orthogonal structure, as well as 9R orthogonal and 9R monoclinic structure, coexist in a single Cu-rich nano precipitate. Further analyses pointed out that Cu-rich nano precipitates of bcc structure were not stable, it may preferentially transform to 9R orthogonal structure and then to 9R monoclinic structure. This results showed that the crystal structure evolution of the Cu-rich nano precipitates was complex.
文摘Background and Objective. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through the addition of peptides, such as sinapultide, that mimic the action of human surfactant protein-B (SP-B). A synthetic surfactant containing a mimic of SP-B may also reduce the potential risks associated with the use of animal-derived products. Our objective was to compare the efficacy and safety of a novel synthetic surfactant containing a functional SP-B mimic (lucinactant; Discovery Laboratories, Doylestown, PA) with those of a non-protein-containing synthetic surfactant (colfosceril palmitate; Glaxo Smith Kline, Brentford, United Kingdom) and a bovine-derived surfactant (beractant; Abbott Laboratories, Abbott Park, IL) in the prevention of neonatal respiratory distress syndrome (RDS) and RDS-related death. Methods. We assigned randomly (double-masked) 1294 very preterm infants, weighing 600 to 1250 g and of ≤32 weeks gestational age, to receive colfosceril palmitate (n=509), lucinactant (n=527), or beractant (n=258) within 20 to 30 minutes after birth. Primary outcome measures were the rates of RDS at 24 hours and the rates of death related to RDS during the first 14 days after birth. All-cause mortality rates, bronchopulmonary dysplasia (BPD) rates, and rates of other complications of prematurity were prespecified secondary outcomes. Primary outcomes, air leaks, and causes of death were assigned by an independent, masked, adjudication committee with prespecified definitions. The study was monitored by an independent data safety monitoring board. Results. Lucinactant reduced significantly the incidence of RDS at 24 hours,compared with colfosceril (39.1%vs 47.2%; odds ratio [OR]: 0.68; 95%confidence interval [CI]: 0.52-0.89). There was no significant difference in comparison with beractant (33.3%). However, lucinactant reduced significantly RDS-related mortality rates by 14 days of life, compared with both colfosceril (4.7%vs 9.4%; OR: 0.43; 95%CI: 0.25-0.73) and beractant (10.5%; OR: 0.35; 95%CI: 0.18-0.66). In addition, BPD at 36 weeks postmenstrual age was significantly less common with lucinactant than with colfosceril (40.2%vs 45.0%; OR: 0.75; 95%CI: 0.56-0.99), and the all-cause mortality rate at 36 weeks postmenstrual age was lower with lucinactant than with beractant (21%vs 26%; OR: 0.67; 95%CI: 0.45-1.00). Conclusions. Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS. In addition, lucinactant reduces the incidence of BPD, compared with colfosceril palmitate, and decreases RDS-related mortality rates, compared with beractant. Therefore, we conclude that lucinactant, the first of a new class of surfactants containing a functional protein analog of SP-B, is an effective therapeutic option for preterm infants at risk for RDS.
